Whereas, on June 13, 2017, the U.S. Senate Committee on Health, Education, Labor, and Pensions held a hearing entitled, The Cost of Prescription Drugs: How the Drug Delivery System Affects What Patients Pay ; Whereas, on October 17, 2017, the U.S. Senate Committee on Health, Education, Labor, and Pensions held a hearing entitled, The Cost of Prescription Drugs: How the Drug Delivery System Affects What Patients Pay, Part II ; Whereas, on December 12, 2017, the U.S. Senate Committee on Health, Education, Labor, and Pensions held a hearing entitled, The Cost of Prescription Drugs: An Examination of The National Academies of Sciences, Engineering, and Medicine Report Making Medicines Affordable: A National Imperative ; Whereas, on December 13, 2017, the U.S. House of Representatives Committee on Energy and Commerce, Subcommittee on Health, held a hearing on Examining the Drug Supply Chain ; Whereas, on May 11, 2018, President Donald Trump and Health and Human Services Secretary Alex Azar introduced the American Patients First blueprint to bring down prescription drug prices; Whereas American patients deserve more transparency and information to better position them to be well-informed participants in their health care decision making as they consult with their physician or other licensed health care practitioner; Whereas the Centers for Medicare & Medicaid Services is the single largest payor for drugs in the United States; Whereas, in 2016, the Centers for Medicare & Medicaid Services and its beneficiaries spent over $174 billion on drugs covered under Parts B and D, and $64 billion on drugs covered under Medicaid, for a total of more than $238 billion for prescription drugs; Whereas, in 2017, drug manufacturers spent over $5.5 billion on prescription drug advertising of which nearly $4.2 billion was spent on television advertising; and Whereas the ten most commonly advertised drugs have list prices ranging from $535 to $11,000 per month or usual course of therapy: Now, therefore, be it